Sarcopenia and nutritional impact in pediatric patients with chronic liver disease: Clinical and management strategies

Abstract Sarcopenia, a progressive skeletal muscle disorder characterized by the decline in muscle strength, mass, and function, is increasingly recognized in pediatric chronic liver disease (CLD) as a marker of poor clinical outcomes. Its pathogenesis is multifactorial, involving malnutrition, systemic inflammation, hormonal imbalances, hypermetabolism, impaired protein synthesis, and micronutrient deficiencies. A related entity, sarcopenic obesity notably observed in metabolic‐associated steatotic liver disease adds further complexity by combining muscle loss with excess adiposity, insulin resistance, and inflammation. Assessment of sarcopenia in children currently relies on a combination of imaging modalities and functional evaluations. Nutritional strategies to mitigate sarcopenia include tailored macronutrient intake (e.g., adequate protein, branched‐chain amino acids, and medium‐chain triglycerides), supplementation with key micronutrients (such as vitamin D and zinc), and structured physical activity programs. Emerging evidence supports integrating sarcopenia screening into routine clinical care, particularly during liver transplant evaluation. Given the limited consolidated evidence on the interplay between sarcopenia, liver dysfunction, and nutrition in children, the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition Hepatology and Nutrition Committees have conducted a comprehensive review to provide updated guidance on the diagnosis and nutritional management of sarcopenia in pediatric CLD.